BALAXI · NSE
BALAXI PHARMACEUTICALS LIMITED
₹22.73
-0.92% (-₹0.21)
Prev. close
₹22.94
Volume
20,375
Delivery %
90.3%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Hyderabad
Website
balaxipharma.inExchange
View on NSE ↗Key stats
Market cap
₹126.76 Cr
P/E ratio (TTM)
51.0
EPS (TTM)
₹0.45
Beta (1Y · daily vs NIFTY 50)
0.94
Beta (5Y · monthly vs NIFTY 50)
1.84
Shares float
96.52 L
EPS · quarter ended Jun 2026
₹0.24
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with NSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with NSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹231.33 Cr | ₹279.39 Cr | ₹336.43 Cr | ₹241.29 Cr | ₹292.56 Cr | ₹270.17 Cr | |
| EBITDA | ₹44.64 Cr | ₹55.18 Cr | ₹59.17 Cr | ₹5.79 Cr | ₹33.50 Cr | ₹11.35 Cr |
| ₹38.14 Cr | ₹47.66 Cr | ₹45.96 Cr | ₹-2.39 Cr | ₹25.07 Cr | ₹1.42 Cr | |
| Diluted EPS | ₹7.63 | ₹9.53 | ₹9.08 | ₹-2.32 | ₹4.54 | ₹0.26 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹100.00 Cr | ₹176.00 Cr | ₹240.00 Cr | ₹258.00 Cr | ₹310.00 Cr | ₹337.00 Cr | |
| ₹3.66 Cr | ₹3.64 Cr | ₹13.31 Cr | ₹19.40 Cr | ₹53.43 Cr | ₹57.65 Cr | |
| Stockholders' equity | ₹65.00 Cr | ₹113.00 Cr | ₹183.00 Cr | ₹201.00 Cr | ₹232.00 Cr | ₹249.00 Cr |
Current assets, Trade receivables, Non-current assets, CWIP, Others, Long-term debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹32,000 | ₹34.14 Cr | ₹6.08 Cr | ₹4.87 Cr | ₹-35.00 Cr | ₹-4.50 Cr | |
| Investing cash flow | ₹-5.97 Cr | ₹-28.45 Cr | ₹-10.57 Cr | ₹-1.05 Cr | ₹-21.76 Cr | ₹-20.78 Cr |
| ₹3.65 Cr | ₹-16.27 L | ₹25.51 Cr | ₹30.25 Cr | ₹33.88 Cr | ₹43.96 L | |
| Capital expenditure | ₹-1.28 Cr | ₹-4.75 Cr | ₹-14.98 Cr | ₹-69.27 L | ₹-21.76 Cr | ₹-42.85 Cr |
| End cash position | ₹1.67 Cr | ₹7.19 Cr | ₹28.21 Cr | ₹62.29 Cr | ₹39.40 Cr | ₹14.56 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Sep 22(3Q) | Dec 22 | Mar 23 | May 23–Dec 23(4Q) | Feb 24 | Mar 24 | Apr 24 | Jun 24–Jun 26(9Q) |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.86% | 72.86% | 72.86% | 72.69% | 71.57% | 71.22% | 67.80% | 66.86% | 66.36% | 65.99% |
| Public | 27.13% | 27.12% | 27.14% | 27.31% | 28.43% | 28.78% | 32.20% | 33.14% | 33.64% | 34.01% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| BALAXI PHARMACEUTICALS LIMITED | ₹126.98 Cr | ₹22.73 | 51.1 | 0.51 | 0.6% | 0.23 | -7.7% | -49.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 11
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Balaxi Pharma Yearly results, Financial Summary
Balaxi Pharmaceuticals Ltd. reported a 42.92% increase in Profit After Tax (PAT) to Rs 5.15 crore for the year. Total income rose by 36.40% to Rs 90.52 crore, while Earnings Before Interest and Taxes (EBIT) grew by 32.45% to Rs 9.73 crore. These figures reflect the company's annual financial performance.